ADMA - ADMA Biologics, Inc.
| Previous Close | 4.1300 |
| Open | 4.1700 |
| Bid | 4.1600 x 2200 |
| Ask | 12.8000 x 3100 |
| Day's Range | 4.0700 - 4.3500 |
| 52 Week Range | 2.0800 - 6.3130 |
| Volume | 834,541 |
| Avg. Volume | 771,860 |
| Market Cap | 256.256M |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0910 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.19 |
- GlobeNewswire
ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to.
- Simply Wall St.
Here's Why ADMA Biologics (NASDAQ:ADMA) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- GlobeNewswire
ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA.
- GlobeNewswire
ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been accepted as a member of the Plasma Protein Therapeutics Association (PPTA) as a North America Member effective January 1, 2020. Adam Grossman, President and CEO of ADMA, will join the PPTA North America Board of Directors.
- American City Business Journals
Publicly traded biotechnology company to add 100 jobs in South Florida
ADMA Biologics, a late-stage biotechnology, will add new jobs to its Boca Raton campus. The Business Development Board of Palm Beach County on Monday announced that the Ramsey, New Jersey-based company (Nasdaq: ADMA) will increase its number of workers there to 350 with help from the economic development agency. It currently has 250 workers in Boca Raton.
- GlobeNewswire
ADMA Biologics Named Company of the Year by BioFlorida
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.
- GlobeNewswire
ADMA Biologics Announces First Commercial Sales of ASCENIV™
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to.
- GlobeNewswire
ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV™ in the peer reviewed journal Immunotherapy.
- Simply Wall St.
Should You Worry About ADMA Biologics, Inc.'s (NASDAQ:ADMA) CEO Salary Level?
Adam Grossman became the CEO of ADMA Biologics, Inc. (NASDAQ:ADMA) in 2011. This report will, first, examine the CEO...
- GlobeNewswire
ADMA Biologics Announces Data Presented at IDWeek 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.
- GlobeNewswire
ADMA Biologics Announces Poster Presentation at IDWeek 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.
- GlobeNewswire
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that Adam Grossman, President and Chief Executive Officer, and Brian Lenz, Executive Vice President and Chief Financial Officer, are scheduled to present a corporate overview at the Cantor Global Healthcare Conference, to be held October 2-4, 2019, at the InterContinental New York Barclay, in New York City. ADMA is scheduled to present on Wednesday, October 2, 2019 at 10:40 AM ET.
- Simply Wall St.
What Kind Of Investor Owns Most Of ADMA Biologics, Inc. (NASDAQ:ADMA)?
A look at the shareholders of ADMA Biologics, Inc. (NASDAQ:ADMA) can tell us which group is most powerful. Generally...
- GlobeNewswire
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.
- Simply Wall St.
Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)
ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company...
- GlobeNewswire
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.
- GlobeNewswire
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.
- Simply Wall St.
Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Simply Wall St.
How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- GuruFocus.com
ADMA Biologics: Selloff Creates Buying Opportunity
The fundamental growth story is intact
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
- GuruFocus.com
ADMA Biologics Is De-Risked and Ready to Rise
After years of struggle, ADMA Biologics (ADMA) appears at last to be poised for bigger things. The Food and Drug Administration's recent approval of two of its intravenous immune globulin (IVIG) drug products, Asceniv and Bivigam, has put this stock back on the radar. Combined with a timely capital raise, ADMA's two new products should set it up for an impressive breakout in the second half of 2019.
- GlobeNewswire
ADMA Biologics to Present at Upcoming Investor Conferences
Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, Fla., May 29, 2019 -- ADMA Biologics, Inc. (NASDAQ:.
- TheStreet.com
These 3 Biotech Stocks Are Attracting Insider Buying
Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.
- GlobeNewswire
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
